Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme

Report of the 2001 data from 15 United States medical centres

Paul R. Rhomberg, Ronald N. Jones, Helio S. Sader, T. Beavers-May, L. Steele-Moore, P. Della-Latta, L. Lee, S. Cavalieri, M. Wilson, P. Tierno, L. Peterson, G. Pankey, J. Bradley, M. Jacobs, M. A. Pfaller, K. Rolston, Karen C Carroll, D. Sewell, P. Schoch

Research output: Contribution to journalArticle

Abstract

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme is an international surveillance network of more than 100 medical centres where meropenem is the primary therapeutic carbapenem. Institutions have been monitored since 1997 (1999 in United States (US)) using National Committee for Clinical Laboratory Standards (NCCLS) reference susceptibility methods to monitor in vitro activity of meropenem and selected other broad-spectrum antimicrobial agents. In 2001, a total of 2874 strains were processed from the 15 US medical centres. Molecular methods were associated with MIC methods as needed for defining epidemic spread of resistant strains. The meropenem MIC90 values were 0.03mg/l for Citrobacter spp., Escherichia coli and Klebsiella spp.; 0.06mg/l for Proteus mirabilis and Serratia spp. and 0.12mg/l for Enterobacter spp. This potency was 8-16-fold greater than that of imipenem and the meropenem spectrum of activity versus the Enterobacteriaceae was the broadest of all tested antimicrobial agents. Only piperacillin/tazobactam (MIC9, 64mg/l) and tobramycin (MIC 90, 4mg/l) were active against more than 90.0% of Pseudomonas aeruginosa at the NCCLS susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. However, Acinetobacter spp. isolates were resistant to all of the antimicrobial agents tested and the molecular typing results suggested that they were epidemiologically related. Only ciprofloxacin and ceftazidime had significantly reduced activity against oxacillin-susceptible staphylococci (87.9-92.6% susceptible. These 2001 US MYSTIC Programme results demonstrated no significant decline in carbapenem activity or susceptibility rates compared with the previously monitored years (1999-2000). Most apparent were the decreasing susceptibility rates for ciprofloxacin and ceftazidime against staphylococci. Continued surveillance in these institutions appears warranted as sites of high potential emerging resistance risk.

Original languageEnglish (US)
Pages (from-to)52-59
Number of pages8
JournalInternational Journal of Antimicrobial Agents
Volume23
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

meropenem
Carbapenems
Anti-Infective Agents
Acinetobacter
Ceftazidime
Ciprofloxacin
Staphylococcus
Citrobacter
Serratia
Molecular Typing
Oxacillin
Proteus mirabilis
Enterobacter
Tobramycin
Klebsiella
Imipenem
Enterobacteriaceae
Pseudomonas aeruginosa
Escherichia coli

Keywords

  • Carbapenem
  • Meropenem
  • Surveillance
  • Susceptibility

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme : Report of the 2001 data from 15 United States medical centres. / Rhomberg, Paul R.; Jones, Ronald N.; Sader, Helio S.; Beavers-May, T.; Steele-Moore, L.; Della-Latta, P.; Lee, L.; Cavalieri, S.; Wilson, M.; Tierno, P.; Peterson, L.; Pankey, G.; Bradley, J.; Jacobs, M.; Pfaller, M. A.; Rolston, K.; Carroll, Karen C; Sewell, D.; Schoch, P.

In: International Journal of Antimicrobial Agents, Vol. 23, No. 1, 01.2004, p. 52-59.

Research output: Contribution to journalArticle

Rhomberg, PR, Jones, RN, Sader, HS, Beavers-May, T, Steele-Moore, L, Della-Latta, P, Lee, L, Cavalieri, S, Wilson, M, Tierno, P, Peterson, L, Pankey, G, Bradley, J, Jacobs, M, Pfaller, MA, Rolston, K, Carroll, KC, Sewell, D & Schoch, P 2004, 'Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States medical centres', International Journal of Antimicrobial Agents, vol. 23, no. 1, pp. 52-59. https://doi.org/10.1016/j.ijantimicag.2003.05.010
Rhomberg, Paul R. ; Jones, Ronald N. ; Sader, Helio S. ; Beavers-May, T. ; Steele-Moore, L. ; Della-Latta, P. ; Lee, L. ; Cavalieri, S. ; Wilson, M. ; Tierno, P. ; Peterson, L. ; Pankey, G. ; Bradley, J. ; Jacobs, M. ; Pfaller, M. A. ; Rolston, K. ; Carroll, Karen C ; Sewell, D. ; Schoch, P. / Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme : Report of the 2001 data from 15 United States medical centres. In: International Journal of Antimicrobial Agents. 2004 ; Vol. 23, No. 1. pp. 52-59.
@article{c3672e0541414975a496ad5cc3ccc304,
title = "Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States medical centres",
abstract = "The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme is an international surveillance network of more than 100 medical centres where meropenem is the primary therapeutic carbapenem. Institutions have been monitored since 1997 (1999 in United States (US)) using National Committee for Clinical Laboratory Standards (NCCLS) reference susceptibility methods to monitor in vitro activity of meropenem and selected other broad-spectrum antimicrobial agents. In 2001, a total of 2874 strains were processed from the 15 US medical centres. Molecular methods were associated with MIC methods as needed for defining epidemic spread of resistant strains. The meropenem MIC90 values were 0.03mg/l for Citrobacter spp., Escherichia coli and Klebsiella spp.; 0.06mg/l for Proteus mirabilis and Serratia spp. and 0.12mg/l for Enterobacter spp. This potency was 8-16-fold greater than that of imipenem and the meropenem spectrum of activity versus the Enterobacteriaceae was the broadest of all tested antimicrobial agents. Only piperacillin/tazobactam (MIC9, 64mg/l) and tobramycin (MIC 90, 4mg/l) were active against more than 90.0{\%} of Pseudomonas aeruginosa at the NCCLS susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. However, Acinetobacter spp. isolates were resistant to all of the antimicrobial agents tested and the molecular typing results suggested that they were epidemiologically related. Only ciprofloxacin and ceftazidime had significantly reduced activity against oxacillin-susceptible staphylococci (87.9-92.6{\%} susceptible. These 2001 US MYSTIC Programme results demonstrated no significant decline in carbapenem activity or susceptibility rates compared with the previously monitored years (1999-2000). Most apparent were the decreasing susceptibility rates for ciprofloxacin and ceftazidime against staphylococci. Continued surveillance in these institutions appears warranted as sites of high potential emerging resistance risk.",
keywords = "Carbapenem, Meropenem, Surveillance, Susceptibility",
author = "Rhomberg, {Paul R.} and Jones, {Ronald N.} and Sader, {Helio S.} and T. Beavers-May and L. Steele-Moore and P. Della-Latta and L. Lee and S. Cavalieri and M. Wilson and P. Tierno and L. Peterson and G. Pankey and J. Bradley and M. Jacobs and Pfaller, {M. A.} and K. Rolston and Carroll, {Karen C} and D. Sewell and P. Schoch",
year = "2004",
month = "1",
doi = "10.1016/j.ijantimicag.2003.05.010",
language = "English (US)",
volume = "23",
pages = "52--59",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme

T2 - Report of the 2001 data from 15 United States medical centres

AU - Rhomberg, Paul R.

AU - Jones, Ronald N.

AU - Sader, Helio S.

AU - Beavers-May, T.

AU - Steele-Moore, L.

AU - Della-Latta, P.

AU - Lee, L.

AU - Cavalieri, S.

AU - Wilson, M.

AU - Tierno, P.

AU - Peterson, L.

AU - Pankey, G.

AU - Bradley, J.

AU - Jacobs, M.

AU - Pfaller, M. A.

AU - Rolston, K.

AU - Carroll, Karen C

AU - Sewell, D.

AU - Schoch, P.

PY - 2004/1

Y1 - 2004/1

N2 - The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme is an international surveillance network of more than 100 medical centres where meropenem is the primary therapeutic carbapenem. Institutions have been monitored since 1997 (1999 in United States (US)) using National Committee for Clinical Laboratory Standards (NCCLS) reference susceptibility methods to monitor in vitro activity of meropenem and selected other broad-spectrum antimicrobial agents. In 2001, a total of 2874 strains were processed from the 15 US medical centres. Molecular methods were associated with MIC methods as needed for defining epidemic spread of resistant strains. The meropenem MIC90 values were 0.03mg/l for Citrobacter spp., Escherichia coli and Klebsiella spp.; 0.06mg/l for Proteus mirabilis and Serratia spp. and 0.12mg/l for Enterobacter spp. This potency was 8-16-fold greater than that of imipenem and the meropenem spectrum of activity versus the Enterobacteriaceae was the broadest of all tested antimicrobial agents. Only piperacillin/tazobactam (MIC9, 64mg/l) and tobramycin (MIC 90, 4mg/l) were active against more than 90.0% of Pseudomonas aeruginosa at the NCCLS susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. However, Acinetobacter spp. isolates were resistant to all of the antimicrobial agents tested and the molecular typing results suggested that they were epidemiologically related. Only ciprofloxacin and ceftazidime had significantly reduced activity against oxacillin-susceptible staphylococci (87.9-92.6% susceptible. These 2001 US MYSTIC Programme results demonstrated no significant decline in carbapenem activity or susceptibility rates compared with the previously monitored years (1999-2000). Most apparent were the decreasing susceptibility rates for ciprofloxacin and ceftazidime against staphylococci. Continued surveillance in these institutions appears warranted as sites of high potential emerging resistance risk.

AB - The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme is an international surveillance network of more than 100 medical centres where meropenem is the primary therapeutic carbapenem. Institutions have been monitored since 1997 (1999 in United States (US)) using National Committee for Clinical Laboratory Standards (NCCLS) reference susceptibility methods to monitor in vitro activity of meropenem and selected other broad-spectrum antimicrobial agents. In 2001, a total of 2874 strains were processed from the 15 US medical centres. Molecular methods were associated with MIC methods as needed for defining epidemic spread of resistant strains. The meropenem MIC90 values were 0.03mg/l for Citrobacter spp., Escherichia coli and Klebsiella spp.; 0.06mg/l for Proteus mirabilis and Serratia spp. and 0.12mg/l for Enterobacter spp. This potency was 8-16-fold greater than that of imipenem and the meropenem spectrum of activity versus the Enterobacteriaceae was the broadest of all tested antimicrobial agents. Only piperacillin/tazobactam (MIC9, 64mg/l) and tobramycin (MIC 90, 4mg/l) were active against more than 90.0% of Pseudomonas aeruginosa at the NCCLS susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. However, Acinetobacter spp. isolates were resistant to all of the antimicrobial agents tested and the molecular typing results suggested that they were epidemiologically related. Only ciprofloxacin and ceftazidime had significantly reduced activity against oxacillin-susceptible staphylococci (87.9-92.6% susceptible. These 2001 US MYSTIC Programme results demonstrated no significant decline in carbapenem activity or susceptibility rates compared with the previously monitored years (1999-2000). Most apparent were the decreasing susceptibility rates for ciprofloxacin and ceftazidime against staphylococci. Continued surveillance in these institutions appears warranted as sites of high potential emerging resistance risk.

KW - Carbapenem

KW - Meropenem

KW - Surveillance

KW - Susceptibility

UR - http://www.scopus.com/inward/record.url?scp=9144238410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144238410&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2003.05.010

DO - 10.1016/j.ijantimicag.2003.05.010

M3 - Article

VL - 23

SP - 52

EP - 59

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 1

ER -